Elanco US Inc.’s $885 Million Acquisition of Boehringer Ingelheim Vetmedica’s U.S. feline, canine and rabies vaccines portfolio

Ambrogio Visconti

Paul Hastings LLP represented Elanco US Inc., a division of Eli Lilly and Company, in the completion of its approximately $885 million acquisition of Boehringer Ingelheim…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Avatar

Author: Ambrogio Visconti

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here